FGFR2 and urothelial carcinoma: Similar findings were observed for FGFR3 translocations in urothelial carcinoma and for FGFR2 fusions in cholangiocarcinoma, where the lack of the 3′ end of the FGFR transcript being fused to another partner gene delays the micoRNA-mediated degradation of the fusion transcript and, thus, increases FGFR fusion gene tumor expression levels accordingly.